الولايات المتحدة · مجلات اقتصادية · Markets Insider (Business Insider)

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNAâ¢ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...

نشره Markets Insider (Business Insider) · الولايات المتحدة منذ 1 س

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and…

اقرأ المقال كاملًا على Markets Insider (Business Insider) سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (markets.businessinsider.com)

يستحق القراءة أيضًا

Kiplinger

3 Changes to Treasury Direct You Need to Know

Inc.

Emma Grede Built Good American Around Jeans. Now She’s Thinking Bigger

Entrepreneur

Wendy’s Hopes to Win Back Customers by Serving Up the Past With Its ‘Iconic’ Dave’s Single Combo Meal for $7.99

Quartz

Jensen Huang pushed back on 2029 memory glut fears amid stock selloff

Fortune

My industry wants you to fire your sales team. One of my customers plans to double theirs

Fast Company

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNAâ¢ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...

مشاركة